How The Parts Add Up: VONE Targets $274
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 22 2024
0mins
Source: NASDAQ.COM
Vanguard Russell 1000 ETF Analysis: The Vanguard Russell 1000 ETF (VONE) has an implied analyst target price of $274.39, indicating a potential upside of 10.34% from its current trading price of $248.67.
Notable Holdings with Upside Potential: Key holdings within VONE, such as Apellis Pharmaceuticals (APLS), Peloton Interactive (PTON), and Intra-Cellular Therapies (ITCI), show significant upside potential based on analysts' target prices, suggesting optimism about their future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to fall
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 41.030
Low
19.00
Averages
31.69
High
48.00
Current: 41.030
Low
19.00
Averages
31.69
High
48.00
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Acquisition Completed: Biogen successfully completed the acquisition of Apellis Pharmaceuticals on May 14, 2026, making it a wholly-owned subsidiary, significantly enhancing Biogen's market position in nephrology.
- Revenue Contribution: Apellis's two products, EMPAVELI® and SYFOVRE®, generated $689 million in net product revenue in 2025, which is expected to positively impact Biogen's non-GAAP diluted EPS and drive revenue growth in the coming years.
- Market Expansion Potential: The acquisition not only provides Biogen with an established nephrology commercial infrastructure but also accelerates the launch readiness for felzartamab, with the first Phase 3 trial readout anticipated in the first half of 2027.
- Shareholder Value Enhancement: The acquisition is expected to enhance Biogen's non-GAAP EPS compound annual growth rate, further strengthening the company's competitiveness and shareholder returns in the biopharmaceutical industry.
See More
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Acquisition Finalized: Biogen has successfully completed the acquisition of Apellis Pharmaceuticals, which is now a wholly owned subsidiary, significantly enhancing Biogen's market position in nephrology and expected to drive future revenue growth.
- Product Value Addition: Apellis' two products, EMPAVELI® and SYFOVRE®, generated $689 million in net product revenue in 2025, which is anticipated to positively impact Biogen's non-GAAP diluted EPS, enhancing its future profitability.
- Accelerated Market Readiness: The acquisition allows Biogen to leverage Apellis' established commercial and medical infrastructure to expedite the launch readiness for felzartamab, with the first Phase 3 trial readout expected in the first half of 2027.
- Enhanced Shareholder Returns: This transaction is expected to increase Biogen's non-GAAP EPS compound annual growth rate (CAGR), positively impacting its financial performance in 2027 and further boosting investor confidence.
See More
S&P Dow Jones Indices: Bright Horizons Family Solutions and Remitly Global to be Added to S&P SmallCap 600
S&P Dow Jones Indices: The S&P Dow Jones Indices is a leading provider of financial market indices, known for its comprehensive range of benchmarks.
Bright Horizons Family Solutions: Bright Horizons Family Solutions is a prominent company that offers child care and early education services, catering to families and employers.
Remitly Global: Remitly Global is a financial technology company that specializes in international money transfers, providing services to individuals and businesses.
S&P Small Cap 600: The S&P Small Cap 600 is an index that measures the performance of small-cap companies in the U.S., reflecting the overall health of the small-cap market.
See More
Analysis of XBI ETF Trading Dynamics
- Price Fluctuation Analysis: XBI's 52-week low is $75.68 per share and high is $139.19, with the latest trade at $135.87, indicating stability near the high, which may attract investor interest in its technical performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can influence price movements of the underlying components within the ETF.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, which may involve violations of shareholder rights.
- Shareholder Rights Protection: The transaction between Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Biogen Inc. includes $41.00 per share in cash and two non-transferable rights of $2.00 each, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Merger Impact: Helix Energy Solutions Group, Inc. (NYSE: HLX) is merging with Hornbeck Offshore Services, Inc., resulting in Helix shareholders owning approximately 45% of the combined entity, prompting Halper Sadeh LLC to assess the implications for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, allowing shareholders to consult on their rights and options without upfront costs, ensuring their legal interests are protected.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Rights Protection: Monteverde Law Firm is investigating Citizens National Corporation (CZNL) related to its sale to Peoples Bancorp, Inc., where shareholders are expected to receive 2.10 common shares of Peoples and $8.00 in cash per share, aiming to ensure fair compensation for shareholders in the transaction.
- Merger Transaction Analysis: Helix Energy Solutions Group, Inc. (HLX) is merging with Hornbeck Offshore Services, Inc., which will allow Helix shareholders to own approximately 45% of the combined company, indicating strong competitive positioning post-merger.
- Pharmaceutical Acquisition Dynamics: Apellis Pharmaceuticals, Inc. (APLS) is set to be acquired by Biogen, Inc., with shareholders expected to receive $41.00 per share in cash and two contingent payments of $2.00 each, reflecting confidence in meeting future sales targets.
- Biotech Transaction Progress: Soleno Therapeutics, Inc. (SLNO) is being acquired by Neurocrine Biosciences, Inc., with shareholders expected to receive $53.00 per share in cash, and a shareholder vote scheduled for May 15, 2026, showcasing the company's proactive strategy in the biotech sector.
See More
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Acquisition Completed: Biogen successfully completed the acquisition of Apellis Pharmaceuticals on May 14, 2026, making it a wholly-owned subsidiary, significantly enhancing Biogen's market position in nephrology.
- Revenue Contribution: Apellis's two products, EMPAVELI® and SYFOVRE®, generated $689 million in net product revenue in 2025, which is expected to positively impact Biogen's non-GAAP diluted EPS and drive revenue growth in the coming years.
- Market Expansion Potential: The acquisition not only provides Biogen with an established nephrology commercial infrastructure but also accelerates the launch readiness for felzartamab, with the first Phase 3 trial readout anticipated in the first half of 2027.
- Shareholder Value Enhancement: The acquisition is expected to enhance Biogen's non-GAAP EPS compound annual growth rate, further strengthening the company's competitiveness and shareholder returns in the biopharmaceutical industry.
See More
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Acquisition Finalized: Biogen has successfully completed the acquisition of Apellis Pharmaceuticals, which is now a wholly owned subsidiary, significantly enhancing Biogen's market position in nephrology and expected to drive future revenue growth.
- Product Value Addition: Apellis' two products, EMPAVELI® and SYFOVRE®, generated $689 million in net product revenue in 2025, which is anticipated to positively impact Biogen's non-GAAP diluted EPS, enhancing its future profitability.
- Accelerated Market Readiness: The acquisition allows Biogen to leverage Apellis' established commercial and medical infrastructure to expedite the launch readiness for felzartamab, with the first Phase 3 trial readout expected in the first half of 2027.
- Enhanced Shareholder Returns: This transaction is expected to increase Biogen's non-GAAP EPS compound annual growth rate (CAGR), positively impacting its financial performance in 2027 and further boosting investor confidence.
See More
S&P Dow Jones Indices: Bright Horizons Family Solutions and Remitly Global to be Added to S&P SmallCap 600
S&P Dow Jones Indices: The S&P Dow Jones Indices is a leading provider of financial market indices, known for its comprehensive range of benchmarks.
Bright Horizons Family Solutions: Bright Horizons Family Solutions is a prominent company that offers child care and early education services, catering to families and employers.
Remitly Global: Remitly Global is a financial technology company that specializes in international money transfers, providing services to individuals and businesses.
S&P Small Cap 600: The S&P Small Cap 600 is an index that measures the performance of small-cap companies in the U.S., reflecting the overall health of the small-cap market.
See More
Analysis of XBI ETF Trading Dynamics
- Price Fluctuation Analysis: XBI's 52-week low is $75.68 per share and high is $139.19, with the latest trade at $135.87, indicating stability near the high, which may attract investor interest in its technical performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can influence price movements of the underlying components within the ETF.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, which may involve violations of shareholder rights.
- Shareholder Rights Protection: The transaction between Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Biogen Inc. includes $41.00 per share in cash and two non-transferable rights of $2.00 each, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Merger Impact: Helix Energy Solutions Group, Inc. (NYSE: HLX) is merging with Hornbeck Offshore Services, Inc., resulting in Helix shareholders owning approximately 45% of the combined entity, prompting Halper Sadeh LLC to assess the implications for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, allowing shareholders to consult on their rights and options without upfront costs, ensuring their legal interests are protected.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Rights Protection: Monteverde Law Firm is investigating Citizens National Corporation (CZNL) related to its sale to Peoples Bancorp, Inc., where shareholders are expected to receive 2.10 common shares of Peoples and $8.00 in cash per share, aiming to ensure fair compensation for shareholders in the transaction.
- Merger Transaction Analysis: Helix Energy Solutions Group, Inc. (HLX) is merging with Hornbeck Offshore Services, Inc., which will allow Helix shareholders to own approximately 45% of the combined company, indicating strong competitive positioning post-merger.
- Pharmaceutical Acquisition Dynamics: Apellis Pharmaceuticals, Inc. (APLS) is set to be acquired by Biogen, Inc., with shareholders expected to receive $41.00 per share in cash and two contingent payments of $2.00 each, reflecting confidence in meeting future sales targets.
- Biotech Transaction Progress: Soleno Therapeutics, Inc. (SLNO) is being acquired by Neurocrine Biosciences, Inc., with shareholders expected to receive $53.00 per share in cash, and a shareholder vote scheduled for May 15, 2026, showcasing the company's proactive strategy in the biotech sector.
See More
